240 related articles for article (PubMed ID: 11843281)
1. Successful unrelated bone marrow transplantation after arsenic trioxide treatment in a patient with relapsed acute promyelocytic leukemia.
Mikoshiba M; Ohashi K; Takei N; Okuyama Y; Maeda Y; Hiruma K; Akiyama H; Fukuhara O; Takeshita A; Sakamaki H
Int J Hematol; 2002 Jan; 75(1):104-6. PubMed ID: 11843281
[No Abstract] [Full Text] [Related]
2. Prolonged molecular remission after arsenic trioxide and all-trans retinoic acid for acute promyelocytic leukemia relapsed after allogeneic stem cell transplantation.
Grigg A; Kimber R; Szer J
Leukemia; 2003 Sep; 17(9):1916-7; author reply 1918. PubMed ID: 12970801
[No Abstract] [Full Text] [Related]
3. Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide.
Sanford D; Lo-Coco F; Sanz MA; Di Bona E; Coutre S; Altman JK; Wetzler M; Allen SL; Ravandi F; Kantarjian H; Cortes JE
Br J Haematol; 2015 Nov; 171(4):471-7. PubMed ID: 26205361
[TBL] [Abstract][Full Text] [Related]
4. Molecular remission and reconstitution of a full chimera with arsenic trioxide in a patient with acute promyelocytic leukemia relapsed after allogeneic bone marrow transplantation.
Tedeschi A; Cairoli R; Marenco P; Nosari A; Tresoldi E; Di Bona E; Montillo M; Morra E
Leukemia; 2002 Dec; 16(12):2455-6. PubMed ID: 12454753
[No Abstract] [Full Text] [Related]
5. Comparison of clinical outcomes of patients with relapsed acute promyelocytic leukemia induced with arsenic trioxide and consolidated with either an autologous stem cell transplant or an arsenic trioxide-based regimen.
Thirugnanam R; George B; Chendamarai E; Lakshmi KM; Balasubramanian P; Viswabandya A; Srivastava A; Chandy M; Mathews V
Biol Blood Marrow Transplant; 2009 Nov; 15(11):1479-84. PubMed ID: 19822309
[TBL] [Abstract][Full Text] [Related]
6. Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia.
Thomas X; Pigneux A; Raffoux E; Huguet F; Caillot D; Fenaux P
Haematologica; 2006 Jul; 91(7):996-7. PubMed ID: 16757416
[TBL] [Abstract][Full Text] [Related]
7. Combination brings long-term remission in acute promyelocytic leukemia refractory for both all-trans retinoic acid and arsenic trioxide.
Sasaki M; Sugimoto K; Isobe Y; Oshimi K
Eur J Haematol; 2008 Aug; 81(2):160. PubMed ID: 18363868
[No Abstract] [Full Text] [Related]
8. Treatment of relapsed acute promyelocytic leukemia by arsenic trioxide in Iran.
Alimoghaddam K; Ghavamzadeh A; Jahani M; Mousavi A; Iravani M; Rostami S; Ghaffari H; Hosseini R; Jalili M
Arch Iran Med; 2011 May; 14(3):167-9. PubMed ID: 21529103
[TBL] [Abstract][Full Text] [Related]
9. Successful treatment of a case of relapsed acute promyelocytic leukemia with arsenic trioxide.
Hirayama Y; Koyama R; Nagai T; Ohta H; Kondo A; Ishikawa K; Ishitani K; Matsunaga T; Sakamaki S; Niitsu Y
Intern Med; 2001 Nov; 40(11):1136-9. PubMed ID: 11757771
[TBL] [Abstract][Full Text] [Related]
10. Progress in the treatment of acute promyelocytic leukemia: optimization and obstruction.
Li J; Zhu H; Hu J; Mi J; Chen S; Chen Z; Wang Z
Int J Hematol; 2014 Jul; 100(1):38-50. PubMed ID: 24938378
[TBL] [Abstract][Full Text] [Related]
11. ATRA plus arsenic gets another "A" in APL.
Park JH
Blood; 2012 Aug; 120(8):1535-6. PubMed ID: 22918418
[TBL] [Abstract][Full Text] [Related]
12. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide.
Soignet SL; Maslak P; Wang ZG; Jhanwar S; Calleja E; Dardashti LJ; Corso D; DeBlasio A; Gabrilove J; Scheinberg DA; Pandolfi PP; Warrell RP
N Engl J Med; 1998 Nov; 339(19):1341-8. PubMed ID: 9801394
[TBL] [Abstract][Full Text] [Related]
13. Strategies for the treatment of acute promyelocytic leukemia.
Frankfurt O; Tallman MS
J Natl Compr Canc Netw; 2006 Jan; 4(1):37-50. PubMed ID: 16403403
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of prolonged therapy with combined arsenic trioxide and ATRA for relapse of acute promyelocytic leukemia.
Breccia M; Cicconi L; Minotti C; Latagliata R; Giannì L; Lo-Coco F
Haematologica; 2011 Sep; 96(9):1390-1. PubMed ID: 21659361
[No Abstract] [Full Text] [Related]
15. Arsenic trioxide in the treatment of advanced acute promyelocytic leukemia.
Carmosino I; Latagliata R; Avvisati G; Breccia M; Finolezzi E; Lo Coco F; Petti MC
Haematologica; 2004 May; 89(5):615-7. PubMed ID: 15136230
[TBL] [Abstract][Full Text] [Related]
16. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
Leu L; Mohassel L
Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide (trisenox) therapy for acute promyelocytic leukemia in the setting of hematopoietic stem cell transplantation.
Douer D; Hu W; Giralt S; Lill M; DiPersio J
Oncologist; 2003; 8(2):132-40. PubMed ID: 12697938
[TBL] [Abstract][Full Text] [Related]
18. Oral arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia.
Au WY; Kumana CR; Kou M; Mak R; Chan GC; Lam CW; Kwong YL
Blood; 2003 Jul; 102(1):407-8. PubMed ID: 12814916
[No Abstract] [Full Text] [Related]
19. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
[TBL] [Abstract][Full Text] [Related]
20. Management of acute promyelocytic leukemia.
Tallman MS; Nabhan C
Curr Oncol Rep; 2002 Sep; 4(5):381-9. PubMed ID: 12162911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]